One study compared in vivo levels of GSH in the motor cortex of 11 ALS patients with those in 11 age-matched healthy volunteers and determined that GSH levels were 31% lower in ALS patients than in healthy volunteers (Weiduschat et al., 2014)
This was evident in the LIVE and FIGHT trials, in which liraglutide, despite leading to significant weight loss compared with placebo, failed to demonstrate any beneficial effects on clinical outcomes or left ventricular ejection fraction (LVEF) in patients with HFrEF
Retatrutide increased cAMP in these receptor-transfected cells with affinities of (in nanomolar concentrations): 5.8, 0.06, and 0.78 at GCGR, GIPR, and GLP1-R, respectively (Coskun et al
For example, semaglutide (injectable) and tirzepatide (injectable) produce much larger average weight loss in high-quality human trials than any fiber supplement, but they are prescription injectable medications and not appropriate for everyone